STTK Stock — Shattuck Labs Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 (“DR3”) blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$5.01

Market cap

$510.6M

Cash

$197.3M

Enterprise value

$313.3M

Balance sheet

Cash	$197.3M
Debt	$0.0M
Net cash	$197.3M
Enterprise value	$313.3M
Basic shares	101.8M shares
Fully diluted shares	199.1M shares
Fully diluted market cap	$997.3M
Cash per share	$1.94
Quarterly burn	$10.2M
Cash runway	19.4 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

100.7M

Pre-funded warrants

78.6M

Options

13.6M

RSUs

0.6M

Warrants

3.8M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.7M

FDSO

199.1M

Cap table as of 2026-06-30.

Price history

Loading STTK daily closes…

Loading price history…

Recently reported

SL-325 Phase 2 Mixed · 2026-10-01

SL-325 · crohn's disease

Source release →

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

SL-325

Phase 1 · Active Modality: monoclonal antibody

Target DR3 (Death Receptor 3/TNFRSF25)

Indications

Crohn's disease (Phase 1)

Catalysts

— None
— None

Status note Lead program. Completed a single and multiple ascending dose Phase 1 trial in healthy volunteers; data shared June 2026.

SL-846

Preclinical · Active Modality: bispecific antibody

Target DR3 / IL-23R

Indications

Inflammatory bowel disease and other immune-mediated indications (Preclinical)

Catalysts

— None
— None

Status note Bispecific product candidate binding DR3 and IL-23 receptors. GLP toxicology study in cynomolgus macaques currently underway.

SL-425

Preclinical · Active Modality: monoclonal antibody

Target DR3 (Death Receptor 3/TNFRSF25)

Status note Half-life extended version of SL-325; ongoing IND-enabling chronic GLP toxicity study; further development may be informed by SL-325 Phase 1 data.

SL-172154

Stage not disclosed · Terminated

Status note Discontinued.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SL-325
Lead indication	Crohn's Disease
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07753850	Phase 2	Not yet recruiting	Sponsor	STTK	—	Crohn's Disease	—
NCT07158437	Phase 1	Active, not recruiting	Sponsor	STTK	—	Healthy Volunteers	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Shattuck Labs, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	6,306,127	no change	0.83%	2026-08-14
Frazier Life Sciences	3,750,000	+3,750,000	0.57%	2026-08-14
Boxer Capital	1,000,000	+1,000,000	0.52%	2026-08-14
Sphera Biotech	86,461	-194,325	0.09%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

STTK — Shattuck Labs Inc. ☆